EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Long‐Term Single‐Surgeon Outcomes of 320 Robotic Colorectal Cancer Resections: Safety, Oncologic Reliability, and Cost‐Effectiveness

Igor Monsellato, Teresa Gatto, Marco Lodin, Celeste Del Basso, Marco Palucci, Federico Sangiuolo, Mariantonietta Alagia, Emanuele Tessitore, Irene Gandini, Fabio Benedetti, Fabio Giannone, Gianluca Cassese, Fabrizio Panaro

The International Journal of Medical Robotics and Computer Assisted Surgery · 2025-12 · 21 (6)

DOI: 10.1002/rcs.70126 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Robotic surgery is increasingly adopted for colorectal cancer, but long‐term single‐surgeon data are limited. This study assessed perioperative, oncologic and economic outcomes of a standardised robotic colorectal programme over 9 years. Methods A retrospective cohort of 320 consecutive patients undergoing robotic resection for colorectal malignancy (2016–2025) was analysed. Procedures included right, left, transverse and rectal resections using the da Vinci Si/Xi system. Primary end points were conversion, major complications (Clavien–Dindo ≥ III), 30‐day mortality and R0 resection. Secondary outcomes were operative time, length of stay (LOS), reoperation and model‐based cost‐effectiveness using the Quantify the Impact (QTI) tool. Results Conversion occurred in 1.9%, anastomotic leak in 2.2% and mortality in 1%. R0 resection was 99.7%, median LOS 7 [5–10] days, and reoperation 2.5%. QTI estimated savings of €483 versus laparoscopy and €3181 versus open surgery. Conclusions A standardised robotic colorectal programme achieved safe, reproducible and economically sustainable outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →